{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003507","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.944210+00:00","generated_at":"2026-06-28T09:10:12.688462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chemomab reports Q3 net loss of $3.0M; cash $64.3M; appoints new CEO and CFO","bullets":["Cash and equivalents $64.3M as of Sept 30, 2021; expected to fund operations to mid-2023.","Net loss for Q3 2021 of $3.0M ($0.01/share) vs $1.2M loss in Q3 2020.","R&D expenses $1.5M (up from $1.0M); G&A $1.4M (up from $0.2M) due to public company costs and share-based comp.","Appointed Dale Pfost as CEO and Donald Marvin as CFO/COO; progressing three Phase 2 trials.","Phase 2 data readouts expected: liver fibrosis H1 2022, PSC H2 2022; SSc trial starts early 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003507","json":"https://secwatch.observer/filing/0001178913-21-003507.json","markdown":"https://secwatch.observer/filing/0001178913-21-003507.md","text":"https://secwatch.observer/filing/0001178913-21-003507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003507/0001178913-21-003507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003507/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:10:12.688462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}